| Literature DB >> 30213260 |
Savino Occhionorelli1, Dario Andreotti1, Pierpaola Vallese2, Lucia Morganti3, Domenico Lacavalla1, Elena Forini4, Giovanni Pascale5.
Abstract
BACKGROUND: Lymph node involvement is one of the most important prognostic factors in colon cancer. Twelve is considered the minimum number of lymph nodes necessary to retain reliable tumour staging, but several factors can potentially influence the lymph node harvesting. Emergent surgery for complicated colon cancer (perforation, occlusion, bleeding) could represent an obstacle to reach the benchmark of 12 nodes with an accurate lymphadenectomy. So, an efficient classification system of lymphatic involvement is crucial to define the prognosis, the indication to adjuvant therapy and the follow-up. This is the first study with the aim to evaluate the efficacy of lymph nodes ratio (LNR) and log odds of positive lymph nodes (LODDS) in the prognostic assessment of patients who undergo to urgent surgery for complicated colonic cancer.Entities:
Keywords: Colon cancer; LODDS; Lymph nodes; Survival analysis
Mesh:
Year: 2018 PMID: 30213260 PMCID: PMC6137917 DOI: 10.1186/s12957-018-1483-6
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 2.754
OS results
| Variables |
| % | 5-year OS (%) | Univariate analysis (HR, 95% CI) | Multivariate analysis (HR, 95% CI) | |
|---|---|---|---|---|---|---|
| Sex | 0.3399 | |||||
| M | 98 | 48.52 | 46.94 | |||
| F | 104 | 51.48 | 50.96 | 0.8296 (0.5630–1.2224) | ||
| ASA |
| |||||
| 1 | 1 | 0.51 | ||||
| 2 | 73 | 37.63 | 64.38 | 0.1482 (0.002899–7.5709) | ||
| 3 | 113 | 58.25 | 43.36 | 0.3089 (0.006054–15.7561) | ||
| 4 | 7 | 3.61 | 14.29 | 1.2455 (0.01672–92.7711) | ||
| 5 | 0 | 0 | ||||
| Surgical indication |
| |||||
| Occlusion | 157 | 77.72 | 50.32 | |||
| Perforation | 13 | 6.44 | 23.08 | 2.4624 (0.9303–6.5173) | ||
| Bleeding | 23 | 11.39 | 56.52 | 0.8341 (0.4609–1.5095) | ||
| Other | 9 | 4.45 | 44.44 | 1.2497 (0.4689–3.3308) | ||
| Type of surgery | 0.0905 | |||||
| Right hemicolectomy | 81 | 40.1 | 56.79 | |||
| Left hemicolectomy | 19 | 9.41 | 42.11 | 1.7368 (0.8361–3.6079) | ||
| Sigmoidectomy | 43 | 21.29 | 51.16 | 1.3831 (0.8221–2.3270) | ||
| Segmental resection | 33 | 16.34 | 42.42 | 1.4637 (0.8443–2.5375) | ||
| Hartmann | 17 | 8.42 | 35.29 | 2.2026 (0.9800–4.9504) | ||
| Other | 9 | 4.45 | 33.33 | 2.5408 (0.8140–7.9311) | ||
| Surgeon experience | ||||||
| Expert | 164 | 81.19 | ||||
| Not expert | 38 | 18.81 | ||||
| Istotype | 0.816 | |||||
| Adenocarcinoma NOS | 122 | 60.4 | 48.36 | |||
| Carcinoma with mucinous component | 39 | 19.31 | 43.59 | 0.9936 (0.6030–1.6373) | ||
| Mucinous carcinoma | 28 | 13.86 | 53.57 | 0.7776 (0.4459–1.3563) | ||
| Signet ring cells carcinoma | 2 | 0.99 | 50 | 1.011 (0.1303–7.8436) | ||
| Undifferentiated carcinoma | 0 | 0 | ||||
| Mixed | 4 | 1.98 | 50 | 1.0366 (0.2365–4.5427) | ||
| Other | 7 | 3.46 | 71.43 | 0.4153 (0.1597–1.0801) | ||
| G |
| |||||
| 1 | 8 | 4.06 | 75 | |||
| 2 | 144 | 73.1 | 50.69 | 2.1613 (0.8548–5.4647) | ||
| 3 | 45 | 22.84 | 37.78 | 3.5917 (1.3088–9.8565) | ||
| T |
| |||||
| 1 | 0 | 0 | ||||
| 2 | 7 | 3.46 | 57.14 | |||
| 3 | 134 | 66.34 | 55.22 | 0.779 (0.2395–2.5339) | ||
| 4a | 43 | 21.29 | 27.91 | 1.7467 (0.4998–6.1038) | ||
| 4b | 18 | 8.91 | 50 | 0.9053 (0.2418–3.3899) | ||
| Stage |
| |||||
| I | 4 | 1.98 | 50 | |||
| II | 104 | 51.48 | 57.69 | 0.6444 (0.1411–2.9434) | ||
| III | 94 | 46.53 | 39.36 | 1.1417 (0.2480–5.2562) | ||
| Number of examined lymph nodes | 0,0645 | |||||
| ≥ 12 | 159 | 78.71 | 39.53 | |||
| < 12 | 43 | 21.29 | 51.57 | 0.6614 (0.4012–1.0903) | ||
| N |
| |||||
| 0 | 108 | 53.46 | 57.41 | |||
| 1 | 61 | 30.2 | 42.62 | 1.5446 (0.9951–2.3975) | ||
| 2 | 33 | 16.34 | 33.33 | 2.1957 (1.2084–3.9896) | ||
| LNR |
| |||||
| 0 | 120 | 59.41 | 56.67 | |||
| 1 | 49 | 24.26 | 48.98 | 1.1791 (0.7515–1.8499) | ||
| 2 | 33 | 16.34 | 21.21 | 2.9812 (1.5726–5.6517) | ||
| LODDS |
| |||||
| 0 | 89 | 44.06 | 62.92 | |||
| 1 | 80 | 39.6 | 45 | 1.6684 (1.1060–2.5170) | ||
| 1.7593 (1.0759–2.8767) | ||||||
| 2 | 33 | 16.34 | 21.21 | 3.6757 (1.9145–7.0570) | ||
| 4.2842 (2.4192–7.5869) |
The entries in bold are those with statistical significance (p < 0.05)
DFS results
| Variables |
| % | 5-year DFS (%) | Univariate analysis (HR, 95% CI) | Multivariate analysis (HR, 95% CI) | |
|---|---|---|---|---|---|---|
| Sex |
| |||||
| M | 98 | 48.52 | 65.31 | |||
| F | 104 | 51.48 | 81.73 | 0.5038 (0.2939–0.8639) | ||
| ASA | 0.4824 | |||||
| 1 | 1 | 0.51 | ||||
| 2 | 73 | 37.63 | 71.23 | |||
| 3 | 113 | 58.25 | 76.11 | 0.9383 (0.5326–1.6531) | ||
| 4 | 7 | 3.61 | 71.43 | 2.2056 (0.2657–18.3117) | ||
| 5 | 0 | 0 | ||||
| Surgical indication |
| |||||
| Occlusion | 157 | 77.72 | 73.89 | |||
| Perforation | 13 | 6.44 | 46.15 | 2.9382 (0.8069–10.6997) | ||
| Bleeding | 23 | 11.39 | 91.3 | 0.3116 (0.1368–0.7099) | ||
| Other | 9 | 4.45 | 66.67 | 1.438 (0.3631–5.6956) | ||
| Type of surgery | 0.7739 | |||||
| Right hemicolectomy | 81 | 40.1 | 77.78 | |||
| Left hemicolectomy | 19 | 9.41 | 63.16 | 1.5884 (0.6262–4.0293) | ||
| Sigmoidectomy | 43 | 21.29 | 76.74 | 1.2044 (0.5777–2.5113) | ||
| Segmental resection | 33 | 16.34 | 69.7 | 1.4012 (0.6457–3.0406) | ||
| Hartmann | 17 | 8.42 | 70.59 | 1.7488 (0.5734–5.3333) | ||
| Other | 9 | 4.45 | 66.67 | 1.8544 (0.4404–7.8083) | ||
| Surgeon experience | 0.1181 | |||||
| Expert | 164 | 81.19 | 63.16 | |||
| Not expert | 38 | 18.81 | 76.22 | 0.6192 (0.3081–1.2443) | ||
| Istotype | 0.2991 | |||||
| Adenocarcinoma NOS | 122 | 60.4 | 74.59 | |||
| Carcinoma with mucinous component | 39 | 19.31 | 69.23 | 1.2165 (0.5973–2.4776) | ||
| Mucinous carcinoma | 28 | 13.86 | 78.57 | 0.7532 (0.3477–1.6315) | ||
| Signet ring cells carcinoma | 2 | 0.99 | 50 | 5.2445 (0.06004–458.1240) | ||
| Undifferentiated carcinoma | 0 | 0 | ||||
| Mixed | 4 | 1.98 | 50 | 2.0194 (0.2771–14.7187) | ||
| Other | 7 | 3.46 | 85.71 | 0.4487 (0.1164–1.7303) | ||
| G | 0.2498 | |||||
| 1 | 8 | 4.06 | 87.5 | |||
| 2 | 144 | 73.1 | 75.69 | 2.0746 (0.5407–7.9603) | ||
| 3 | 45 | 22.84 | 68.89 | 3.2203 (0.7561–13.7156) | ||
| T |
| |||||
| 1 | 0 | 0 | ||||
| 2 | 7 | 3.46 | 85.71 | |||
| 3 | 134 | 66.34 | 81.34 | 1.3148 (0.3095–5.5851) | ||
| 4a | 43 | 21.29 | 51.16 | 4.2641 (0.9084–20.0169) | ||
| 4b | 18 | 8.91 | 66.67 | 2.4171 (0.4551–12.8374) | ||
| Stage |
| |||||
| I | 4 | 1.98 | 75 | |||
| II | 104 | 51.48 | 82.69 | 0.7248 (0.1144–4.5923) | ||
| III | 94 | 46.53 | 63.83 | 1.7553 (0.2743–11.2331) | ||
| Number of examined lymph nodes | 0.3275 | |||||
| ≥ 12 | 159 | 78.71 | 81.70 | |||
| < 12 | 43 | 21.29 | 71.70 | 1.4498 (0.7441–2.8248) | ||
| N |
| |||||
| 0 | 108 | 53.46 | 82.41 | |||
| 1 | 61 | 30.2 | 68.85 | 1.9121 (1.0413–3.5111) | ||
| 1.8505 (0.9478–3.6131) | ||||||
| 2 | 33 | 16.34 | 54.55 | 3.4804 (1.5203–7.9677) | ||
| 3.13 (1.5150–6.4668) | ||||||
| LNR |
| |||||
| 0 | 120 | 59.41 | 80.83 | |||
| 1 | 49 | 24.26 | 71.43 | 1.5172 (0.8051–2.8592) | ||
| 2 | 33 | 16.34 | 51.52 | 3.7601 (1.5941–8.8694) | ||
| LODDS |
| |||||
| 0 | 89 | 44.06 | 82.02 | |||
| 1 | 80 | 39.6 | 73.75 | 1.5093 (0.8499–2.6803) | ||
| 2 | 33 | 16.34 | 51.52 | 4.0509 (1.6798–9.7690) |
The entries in bold are those with statistical significance (p < 0.05)
Fig. 1Kaplan-Meier survival curves about overall survival for N0, N1 and N2 patients
Fig. 2Kaplan-Meier survival curves about overall survival for patients stratified by lymph nodes ratio (LNR)
Fig. 3Kaplan-Meier survival curves about overall survival for patients stratified by log odds of positive lymph nodes (LODDS)
Fig. 4Kaplan-Meier survival curves about disease-free survival for N0, N1 and N2 patients
Fig. 5Kaplan-Meier survival curves about disease-free survival for patients stratified by lymph nodes ratio (LNR)
Fig. 6Kaplan-Meier survival curves about disease-free survival for patients stratified by log odds of positive lymph nodes (LODDS)